Tegoprubart is a monoclonal antibody commercialized by Eledon Pharmaceuticals, with a leading Phase II program in Amyotrophic Lateral Sclerosis. According to Globaldata, it is involved in 9 clinical trials, of which 2 were completed, 1 is ongoing, 4 are planned, and 2 were terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Tegoprubart’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

The revenue for Tegoprubart is expected to reach an annual total of $262 mn by 2038 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Tegoprubart Overview

Tegoprubart is under development for the treatment of amyotrophic lateral sclerosis (ALS), IgA nephropathy (IgAN), renal transplantation (kidney transplant rejection) and autoimmune nephritis including lupus nephritis. The drug candidate is a humanized anti-CD40L monoclonal antibody. It acts by targeting CD40 ligand (CD40L). It is administered through intravenous route.

It was also under development for the treatment of focal segmental glomerulosclerosis (FSGS), Type 1 diabetes, islet transplant rejection.

Eledon Pharmaceuticals Overview

Eledon Pharmaceuticals is a biotechnology company. It develops products for the ear, nose, and throat. The company’s lead products are a nasally-administer, combination drug product, and eustachian tube dysfunction, among others. Its galeterone is an oral small molecule drug candidate for the treatment of patients with metastatic castration-resistant prostate cancer. Novus offers an OP-02 surfactant program and an OP-01 foam platform. Its pipeline also includes an androgen receptor degradation agent’s drug discovery program to identify and develop compounds for androgen receptor degradation activity. The company develops treatments for illnesses and disorders of the ears, nose, and throat. It has collaborated with pharmaceutical companies to enhance its product candidates. Eledon Pharmaceuticals is headquartered in Irvine, California, the US.

The operating loss of the company was US$36.9 million in FY2021, compared to an operating loss of US$18.5 million in FY2020. The net loss of the company was US$34.5 million in FY2021, compared to a net loss of US$22.8 million in FY2020.

For a complete picture of Tegoprubart’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.